<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405714</url>
  </required_header>
  <id_info>
    <org_study_id>EP0065</org_study_id>
    <secondary_id>2016-002452-25</secondary_id>
    <nct_id>NCT03405714</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects &gt;= 1 Month to &lt; 16 Years of Age With Epilepsy</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects &gt;= 1 Month &lt; 16 Years of Age With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability&#xD;
      of brivaracetam (BRV) administered intravenously (iv) in subjects &gt;= 1 month to &lt; 16 years of&#xD;
      age with epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">November 4, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events throughout the study</measure>
    <time_frame>From Screening (Day -20 to -1) until last visit (up to day 68)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subject withdrawals due to AEs</measure>
    <time_frame>From Screening (Day -20 to -1) until last visit (up to day 68)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of brivaracetam (BRV)</measure>
    <time_frame>Blood samples will be collected &lt;= 1 hour pre-initiation of intravenous (iv) BRV infusion and 15 min and 3 hours post-initiation of iv BRV infusion.</time_frame>
    <description>Blood samples will be taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brivaracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects &gt;=12 to &lt;16 years; Cohort 2: Subjects &gt;=6 to &lt;12 years; Cohort 3: Subjects &gt;=2 to &lt;6 years; Cohort 4: Subjects 1 month to &lt;2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Pharmaceutical form: Solution for iv injection&#xD;
Route of administration: intravenous use&#xD;
Concentration: 10 mg/ml</description>
    <arm_group_label>Brivaracetam</arm_group_label>
    <other_name>Briviact</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from &gt;= 1 month to &lt; 16 years of age. For subjects who are &lt; 1 year&#xD;
             from birth and who were preterm infants, the corrected gestational age should be used&#xD;
             for this entry requirement&#xD;
&#xD;
          -  Weight &gt;= 3 kg (6.6 lbs)&#xD;
&#xD;
          -  Diagnosis of epilepsy&#xD;
&#xD;
          -  Acceptable candidate for venipuncture and intravenous (iv) infusion&#xD;
&#xD;
          -  Treatment with &gt;=1 anti epileptic drug (AED; including BRV) without a change of dose&#xD;
             regimen for at least 7 days prior to Screening&#xD;
&#xD;
          -  No treatment with vagus nerve stimulation (VNS), OR the subject is being treated with&#xD;
             VNS and the settings have been constant for &gt;=7 days prior to Screening&#xD;
&#xD;
          -  For female subjects: not of childbearing potential, OR of childbearing potential and&#xD;
             not sexually active/negative pregnancy test, OR of childbearing potential and sexually&#xD;
             active/negative pregnancy test/uses medically acceptable contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has previously received iv Brivaracetam (BRV) in this study&#xD;
&#xD;
          -  Subject is being treated with BRV at a dose &gt;5mg/kg/day (rounded) or &gt;200mg/day for&#xD;
             subjects with body weights &gt;40kg&#xD;
&#xD;
          -  Subject requires or is likely to require a change in concomitant antiepileptic drug(s)&#xD;
             (AED[s]), dose of concomitant AED(s), or formulation of AED(s) during the 7 days prior&#xD;
             to the intravenous (iv) pharmacokinetic (PK) Period&#xD;
&#xD;
          -  Subject is likely, in the opinion of the Investigator, to require rescue medication&#xD;
             during the Initiating Oral BRV (IOB) Treatment or iv PK Periods&#xD;
&#xD;
          -  Subject has experienced generalized convulsive status epilepticus in the 28 days prior&#xD;
             to Screening or during the Screening Period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0065 252</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 237</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 502</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 240</name>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 242</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 254</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 210</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 224</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 247</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 222</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 232</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 264</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 238</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 239</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 230</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 223</name>
      <address>
        <city>Aguas Calientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0065 248</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Brivaracetam</keyword>
  <keyword>Briviact</keyword>
  <keyword>Open-label</keyword>
  <keyword>pediatric</keyword>
  <keyword>intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 8, 2021</submitted>
    <returned>October 5, 2021</returned>
    <submitted>October 27, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

